Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Minor snRNA gene delivery improves the loss of proprioceptive synapses on SMA motor neurons
Erkan Y. Osman, Meaghan Van Alstyne, Pei-Fen Yen, Francesco Lotti, Zhihua Feng, Karen K.Y. Ling, Chien-Ping Ko, Livio Pellizzoni, Christian L. Lorson
Erkan Y. Osman, Meaghan Van Alstyne, Pei-Fen Yen, Francesco Lotti, Zhihua Feng, Karen K.Y. Ling, Chien-Ping Ko, Livio Pellizzoni, Christian L. Lorson
View: Text | PDF
Research Article Neuroscience

Minor snRNA gene delivery improves the loss of proprioceptive synapses on SMA motor neurons

  • Text
  • PDF
Abstract

Spinal muscular atrophy (SMA) is an inherited neuromuscular disorder caused by reduced expression of the survival motor neuron (SMN) protein. SMN has key functions in multiple RNA pathways, including the biogenesis of small nuclear ribonucleoproteins that are essential components of both major (U2-dependent) and minor (U12-dependent) spliceosomes. Here we investigated the specific contribution of U12 splicing dysfunction to SMA pathology through selective restoration of this RNA pathway in mouse models of varying phenotypic severity. We show that virus-mediated delivery of minor snRNA genes specifically improves select U12 splicing defects induced by SMN deficiency in cultured mammalian cells, as well as in the spinal cord and dorsal root ganglia of SMA mice without increasing SMN expression. This approach resulted in a moderate amelioration of several parameters of the disease phenotype in SMA mice, including survival, weight gain, and motor function. Importantly, minor snRNA gene delivery improved aberrant splicing of the U12 intron–containing gene Stasimon and rescued the severe loss of proprioceptive sensory synapses on SMA motor neurons, which are early signatures of motor circuit dysfunction in mouse models. Taken together, these findings establish the direct contribution of U12 splicing dysfunction to synaptic deafferentation and motor circuit pathology in SMA.

Authors

Erkan Y. Osman, Meaghan Van Alstyne, Pei-Fen Yen, Francesco Lotti, Zhihua Feng, Karen K.Y. Ling, Chien-Ping Ko, Livio Pellizzoni, Christian L. Lorson

×

Figure 5

Phenotypic analysis of AAV9-mediated minor snRNA gene delivery in mouse models of SMA.

Options: View larger image (or click on image) Download as PowerPoint
Phenotypic analysis of AAV9-mediated minor snRNA gene delivery in mouse ...
(A) AAV-mediated gene delivery of human U11/U12 and U11/U12/U4atac snRNAs prolonged survival of severe SMNΔ7 SMA mice. The Kaplan-Meier survival curve indicates significant life extension for SMNΔ7 SMA mice injected with either AAV9-U11/U12 (orange) or AAV9-U11/U12/U4atac (blue) compared with the untreated SMA mice (red). Unaffected animals (black) and SMA mice injected with AAV9 carrying human full-length SMN (green) were used as a positive control. Healthy littermates were also treated with AAV9-U11/U12 (purple) to test for any potential toxicity of the minor snRNAs. Log-rank Mantel-Cox test (P < 0.0001). (B) The average weight per group is plotted across days for the surviving animals in each cohort. Significant weight gain was observed from P10 through P14 in SMNΔ7 mice injected with AAV9-U11/U12 or AAV9-U11/U12/U4atac relative to untreated SMA mice. Statistical analyses were performed by 2-way ANOVA, where an asterisk denotes significant weight gain difference between snRNAs treated and untreated cohorts (P ≤ 0.03). (C) Scatter plot depicting the percentage weight gained from birth to peak. Analysis of percentage weight gain showed significant improvement in peak weight gain in SMNΔ7 SMA mice injected with AAV9-U11/U12 or AAV9-U11/U12/U4atac relative to untreated SMA mice. Statistics: 1-way ANOVA with Tukey’s post hoc test. (D) Righting reflex measurements. Time-to-right (TTR) measurements were initiated on P6 and recorded along animals’ life span. SMNΔ7 SMA mice injected with AAV9-U11/U12 or AAV9-U11/U12/U4atac showed significantly improved TTR from P12 through P16 relative to untreated SMA mice (P = 0.004; 1-way ANOVA; Tukey’s multiple-comparisons test). *P < 0.05; **P < 0.01; ***P < 0.001; ns, no significance. (E and F) Phenotypic assessment in the intermediate Smn2B/– mouse model after delivery of AAV9 expressing minor splicing snRNAs showed a significant extension in survival (E) and increased weight gain (F). Log-rank Mantel-Cox test (P < 0.0001) for survival measurements.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts